Severe Axonal Polyneuropathy Revealing Eosinophilic Granulomatosis With Polyangiitis: A Case Report and Review of the Literature

Read full text Summarise with VIRAT
Authors: Soumia Ait Ami, Manal Toulite, Yasmina Zakaria, Mohamed Chraa, Nissrine Louhab
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic small- and medium-vessel vasculitis characterized by asthma, hypereosinophilia, and multisystem involvement. Peripheral neuropathy is a recognized neurological manifestation of EGPA and may occasionally present as severe axonal polyneuropathy. We report the case of a 64-year-old male with a 10-year history of asthma who presented with progressive lower limb weakness and paresthesia over three months, which led to wheelchair dependence. Electroneuromyography (ENMG) confirmed a severe axonal sensorimotor polyneuropathy. Laboratory findings showed marked hypereosinophilia (9,030/mm³), strongly positive antineutrophil cytoplasmic antibodies (ANCA), and elevated inflammatory markers. Thoraco-abdominopelvic CT revealed bilateral interstitial and alveolar infiltrates. The diagnosis of EGPA was established according to the American College of Rheumatology (ACR) criteria. Treatment with corticosteroids and cyclophosphamide resulted in significant neurological improvement. This report emphasizes the importance of considering EGPA in asthmatic patients presenting with severe axonal polyneuropathy. Early diagnosis and immunosuppressive therapy are essential to improve outcomes.

Fields of Study & Subjects

Vasculitis and related conditions Peripheral Neuropathies and Disorders Celiac Disease Research and Management

Publication details

Journal / source
Cureus
Volume
18
Issue
3
Pages
e105812–e105812
Publication date
25 March 2026
Language
EN